LANDMARK Trial: a Randomised Controlled Trial of Myval THV
NCT: NCT04275726 · RECRUITING
Brief Summary
The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis. This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves) The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)
Frequently Asked Questions
What is LANDMARK Trial: a Randomised Controlled Trial of Myval THV?
LANDMARK Trial: a Randomised Controlled Trial of Myval THV is a clinical trial registered under NCT04275726. Current status: RECRUITING.
What is the status of NCT04275726?
The current status of NCT04275726 (LANDMARK Trial: a Randomised Controlled Trial of Myval THV) is: RECRUITING.
When did LANDMARK Trial: a Randomised Controlled Trial of Myval THV start?
LANDMARK Trial: a Randomised Controlled Trial of Myval THV started on 2020-11-04.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.